Sanofi: Qfitlia Approval A Bright Spot As Landscape Darkens For European Pharma
Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
sharewise5d
Sanofi Stock: FDA Approves Breakthrough Hemophilia Treatment
Sanofi has received FDA approval for Qfitlia, its innovative hemophilia therapy that represents the first antithrombin-lowering treatment for hemophilia A or B patients with or without inhibitors ...
Pharmabiz6d
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...
Taiwan News6d
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Dupixent is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD. Dupixent is intended for injection under the skin (subcutaneous injection) and ...